Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease.

Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A.

Int Urol Nephrol. 2012 Apr;44(2):541-7. doi: 10.1007/s11255-010-9897-2. Epub 2011 Feb 15.

PMID:
21327525
2.

Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, Muhlestein JB.

Am Heart J. 2011 Aug;162(2):331-339.e2. doi: 10.1016/j.ahj.2011.05.005.

PMID:
21835295
3.

Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).

Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL.

Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S3-10. doi: 10.1053/j.ajkd.2008.11.029.

PMID:
19285609
4.

Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.

Lee SA, Lee MJ, Ryu GW, Jhee JH, Kim HW, Park S, Jung SY, Oh HJ, Park JT, Han SH, Kang SW, Yoo TH.

Osteoporos Int. 2016 Sep;27(9):2717-2726. doi: 10.1007/s00198-016-3636-1. Epub 2016 May 23.

PMID:
27216997
5.

Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.

Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG.

Clin Transplant. 2014 Apr;28(4):479-86. doi: 10.1111/ctr.12341. Epub 2014 Mar 19.

PMID:
25649861
6.

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF.

JAMA. 2011 Mar 16;305(11):1119-27. doi: 10.1001/jama.2011.308. Review.

PMID:
21406649
7.

Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events.

Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A.

Am J Ther. 2013 Sep-Oct;20(5):480-6. doi: 10.1097/MJT.0b013e3182211b3b.

PMID:
22185755
8.

Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate.

Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, Leonard MB.

Clin J Am Soc Nephrol. 2009 Jan;4(1):186-94. doi: 10.2215/CJN.03050608. Epub 2008 Nov 19.

9.

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2014;(12):CD006254. doi: 10.1002/14651858.CD006254.pub2. Epub 2014 Dec 9. Review.

PMID:
25490118
10.

Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival - a single-centre study in a stage 5 chronic kidney disease population.

Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M.

Nephron Clin Pract. 2011;119(2):c113-20. doi: 10.1159/000326683. Epub 2011 Jul 8.

PMID:
21757948
11.

Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease.

Saab G, Whaley-Connell A, McFarlane SI, Li S, Chen SC, Sowers JR, McCullough PA, Bakris GL; Kidney Early Evaluation Program Investigators.

Metabolism. 2010 Mar;59(3):385-9. doi: 10.1016/j.metabol.2009.08.007. Epub 2009 Oct 2.

PMID:
19800639
12.

Posterior urethral valves: Metabolic consequences in a cohort of patients.

Sarhan O, Nakshabandi Z, Alghanbar M, Alotay A, Sherif I, Whitehead C, El-Husseini A.

J Pediatr Urol. 2015 Aug;11(4):216.e1-6. doi: 10.1016/j.jpurol.2015.04.022. Epub 2015 Jun 4.

PMID:
26096436
13.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.

Am J Kidney Dis. 2009 Feb;53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24.

PMID:
19110359
14.

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.

Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1780-6. doi: 10.2215/CJN.02560310. Epub 2010 Jun 24.

15.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
16.

The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.

Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M.

Am J Kidney Dis. 2009 Mar;53(3):408-16. doi: 10.1053/j.ajkd.2008.09.020. Epub 2009 Jan 29.

PMID:
19185400
17.

Disordered FGF23 and mineral metabolism in children with CKD.

Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.

Clin J Am Soc Nephrol. 2014 Feb;9(2):344-53. doi: 10.2215/CJN.05840513. Epub 2013 Dec 5.

18.

Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Kumar N, Lindberg J, David K, Morris J, Menoyo J.

Am J Nephrol. 2009;29(2):71-8. doi: 10.1159/000151275. Epub 2008 Aug 8.

PMID:
18689981
19.

Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.

Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, Hostetter T, Jaar B, Lora CM, Nessel L, Ojo A, Scialla J, Steigerwalt S, Teal V, Wolf M, Rahman M; CRIC Investigators.

Am J Kidney Dis. 2013 Oct;62(4):670-8. doi: 10.1053/j.ajkd.2013.01.017. Epub 2013 Mar 13.

20.

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.

Sonmez A, Yilmaz MI, Saglam M, Unal HU, Gok M, Cetinkaya H, Karaman M, Haymana C, Eyileten T, Oguz Y, Vural A, Rizzo M, Toth PP.

Lipids Health Dis. 2015 Apr 16;14:29. doi: 10.1186/s12944-015-0031-4.

Supplemental Content

Support Center